TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20179232
Drug: Hydrogen sulfate
Normalized name: XYLAN, HYDROGEN SULFATE
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen sulfate (Hyd-Sulfate) capsule
Study: 17268205
Drug: Biventricular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biventricular therapy (biventricular therapy + defibrillator)
Study: 17268205
Drug: Biventricular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biventricular therapy
Study: 12113615
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of rocuronium 0.06 mg kg(‐1) followed 2 min later by rocuronium 0.54 mg kg(‐1)
Study: 12113615
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of 0.10 mg kg(‐1) followed 2 min later by rocuronium 0.50 mg kg(‐1)
Study: 12113615
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of rocuronium 0.06 mg kg(‐1) followed 3 min later by administration 0.54 mg kg(‐1)
Study: 12113615
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of 0.10 mg kg(‐1) followed 3 min later by injection of 0.50 mg kg(‐1)
Study: 12113615
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection followed 3 min later by rocuronium 0.60 mg kg(‐1)
Study: 9585800
Drug: Ritonavir plus
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir plus saquinavir (200 mg saquinavir and 300 mg ritonavir)
Study: 9585800
Drug: Ritonavir plus
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir plus saquinavir (200 mg saquinavir and 600 mg ritonavir)
Study: 9585800
Drug: Ritonavir plus
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir plus saquinavir (400 mg saquinavir and 300 mg ritonavir)
Study: 9585800
Drug: Ritonavir plus
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir plus saquinavir (400 mg saquinavir and 600 mg ritonavir)
Study: 9585800
Drug: Ritonavir plus
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir plus saquinavir (600 mg saquinavir and 200 mg ritonavir)
Study: 9585800
Drug: Ritonavir plus
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir plus saquinavir (600 mg saquinavir and 600 mg ritonavir)
Study: 2146885
Drug: Urodilatin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urodilatin (all doses)
Study: 404621
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin infusion (0.1 units/kg/hour)
Study: 24492859
Drug: Intermittent screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent screening and treatment (IST) for malaria using artemether-lumefantrine (AL) with a six dose regimen.
Study: 24492859
Drug: Intermittent screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent screening and treatment (IST) for malaria.
Study: 17589421
Drug: morphine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine + morphine (MM)
Study: 17589421
Drug: morphine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine + remifentanil (MR)
Study: 10025899
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with alkylating agents
Study: 10025899
Drug: Hydroxyurea and
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea and other non-alkylating agents
Study: 7740509
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Ardeparin) administered subcutaneously
Study: 7740509
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) administered subcutaneously
Study: 7740509
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Ardeparin) administered intravenously
Study: 7740509
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) administered intravenously
Study: 7740509
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Ardeparin)
Study: 7042603
Drug: Rifampin 450
Normalized name: rifampin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 450 mg daily (Regimen A)
Study: 7042603
Drug: Rifampin 1200
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 1200 mg once a month (Regimen B)
Study: 31597662
Drug: ME-344 10
Normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ME-344 10 mg/kg intravenous on days 8, 15, and 21
Study: 28887117
Drug: Intense Pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense Pulsed Light (IPL) treatment (14∼16 J/cm2)
Study: 28887117
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (0 J/cm2)
Study: 21159325
Drug: Self-reported motivation
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-reported motivation measures (Change Questionnaire & Client Motivational for Therapy Scale)
Study: 10561948
Drug: Prenolol 50
Normalized name: alprenolol
DrugBank: Alprenolol (DB00866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenolol 50 mg
Study: 10561948
Drug: Prenolol 100
Normalized name: alprenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenolol 100 mg
Study: 1747577
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg plus slow release nifedipine 20 mg twice daily
Study: 6621623
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of 3500 IU of heparin subcutaneously every eight hours (Group 1)
Study: 6621623
Drug: Adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted dose of heparin to maintain activated partial thromboplastin time between 31.5 and 36 seconds (Group 2)
Study: 31443692
Drug: Remote ischemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote ischemic conditioning (RIC) at 200 mmHg, twice daily for 6 months
Study: 31443692
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group at 60 mmHg, twice daily for 6 months
Study: 28592257
Drug: Maxacalcitol ointment
Normalized name: Paricalcitol
DrugBank: Maxacalcitol (DB06272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maxacalcitol ointment applied twice a day for 8 weeks
Study: 18541125
Drug: Maxacalcitol ointment
Normalized name: Paricalcitol
DrugBank: Maxacalcitol (DB06272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maxacalcitol ointment
Study: 25683077
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 25% dextrose orally just before laser therapy
Study: 25683077
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia with paracaine eye drops
Study: 18639659
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue spray and collagen patch applied to the axillary fossa
Study: 26996929
Drug: Drug-treated hypertension
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-treated hypertension
Study: 11791023
Drug: Drug-treated hypertension
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-treated hypertension with target blood pressure below 130/85
Study: 8610239
Drug: Vinorelbine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m2 on day 1 (Group A)
Study: 8610239
Drug: Vinorelbine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m2 on days 1 and 8 (Group B)
Study: 8610239
Drug: Vinorelbine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m2 on days 1 and 15 and 12.5 mg/m2 on day 8 (Group C)
Study: 1934538
Drug: Ketanserin 10
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 10 mg twice daily
Study: 1981022
Drug: Ketanserin 20
Normalized name: ketanserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 20 mg twice daily
Study: 1934538
Drug: Ketanserin 5
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 5 mg twice daily
Study: 6304907
Drug: Veralipride (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veralipride (100 mg per day for 20 days)
Study: 6304907
Drug: Natural estrogens
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural estrogens (1.25 mg for 20 days)
Study: 30760299
Drug: Internet-based guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based guided self-help (GSH) treatment comprising eight sessions followed by three booster sessions
Study: 30760299
Drug: Placebo-inspired waitlist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-inspired waitlist control group receiving weekly messages with positive expectations
Study: 30760299
Drug: Pure waitlist
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure waitlist control group receiving weekly messages asking to fill in a questionnaire
Study: 27487357
Drug: Pharmacist-led, home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led, home-based medication management intervention delivered within 7 days after hospital discharge
Study: 27487357
Drug: Pharmacist-led, home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led, home-based medication management intervention
Study: 24836205
Drug: Ataluren (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ataluren (10 mg/kg in morning, 10 mg/kg midday, and 20 mg/kg in evening)
Study: 24836205
Drug: Ataluren (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ataluren (in subgroup not using chronic inhaled tobramycin)
Study: 24836205
Drug: Placebo (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (in subgroup not using chronic inhaled tobramycin)
Study: 22854665
Drug: TLR9 agonist
Normalized name: Cmp-001 component cpg-a oligodeoxynucleotide tlr9 agonist
DrugBank: Vidutolimod (DB17500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLR9 agonist (CPG 7909) with pneumococcal conjugate vaccine (Prevnar, Pfizer)
Study: 22854665
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with pneumococcal conjugate vaccine (Prevnar, Pfizer)
Study: 20795842
Drug: Atenolol therapy
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol therapy (100 mg/day for 5 weeks)
Study: 17040921
Drug: GABA(A) receptor
Normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA(A) receptor immunohistochemistry analysis in Huntington's disease cases
Study: 17040921
Drug: GABA(A) receptor
Normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA(A) receptor immunohistochemistry analysis in control cases
Study: 17560868
Drug: E2 1
Normalized name: PGE2 10 MG Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 1 mg plus drospirenone 2 mg
Study: 15090932
Drug: BIA 3-202
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 3-202 (50 mg)
Study: 15090932
Drug: BIA 3-202
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 3-202 (100 mg)
Study: 15090932
Drug: BIA 3-202
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 3-202 (200 mg)
Study: 15090932
Drug: BIA 3-202
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 3-202 (400 mg)
Study: 14517707
Drug: BIA 3-202
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 3-202 (all doses)
Study: 1558774
Drug: Continuous cotrimoxazole
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous cotrimoxazole administration
Study: 1558774
Drug: Intermittent cotrimoxazole
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent cotrimoxazole administration (3 days a week)
Study: 29602225
Drug: Oral microbiota
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral microbiota in children developing allergic disease (asthma)
Study: 29602225
Drug: Oral microbiota
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral microbiota in healthy children
Study: 29602225
Drug: Lactobacillus gasseri
Normalized name: Lactobacillus Gasseri
DrugBank: Lactobacillus gasseri (DB16543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus gasseri and L. crispatus in healthy children
Study: 16298069
Drug: Probable medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probable medication overuse headache (pMOH)
Study: 11964279
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg alternate-day oral prednisone
Study: 11964279
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg alternate-day oral prednisone
Study: 9856375
Drug: Nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine retard (NPA) 10 or 20 mg twice a day
Study: 9856375
Drug: Nifedipine gastrointestinal
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine gastrointestinal therapeutic system (NGITS) 30 or 60 mg once a day
Study: 9856375
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 or 10 mg once a day
Study: 7654468
Drug: Estrogen and
Normalized name: Conjugated estrogen and norgestrel only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen and 1000 mg of supplemental calcium each day
Study: 2762589
Drug: Betamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (1 x 8 mg) and dixyrazine (4 x 10 mg)
Study: 2762589
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide (4 x 1 mg/kg)
Study: 2762589
Drug: Betamethasone-dixyrazine and
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone-dixyrazine and high-dose metoclopramide
Study: 976301
Drug: Isoproterenol (beta-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol (beta-adrenergic receptor stimulatory agent)
Study: 976301
Drug: Propranolol (beta-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (beta-adrenergic receptor blocking agent)
Study: 31995619
Drug: Pembrolizumab combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab combination therapy
Study: 25124565
Drug: CIK cell
Normalized name: Testone CIK KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIK cell therapy
Study: 21812536
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of CpG 7909 (1.05 mg/kg)
Study: 21812536
Drug: Single subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous dose of CpG 7909 (0.45 mg/kg)
Study: 21812536
Drug: Multiple weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Multiple weekly subcutaneous doses of CpG 7909 (0.45 mg/kg)
Study: 21812536
Drug: CpG 7909
Approvals — FDA: no, EMA: no, PMDA: no
Description: CpG 7909 administration
Study: 19294955
Drug: Ramelteon, 8
Normalized name: Ramelteon, 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon, 8 mg nightly for 6 months
Study: 17465861
Drug: Lidocaine (needle-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (needle-free injection)
Study: 14727250
Drug: Concomitant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemotherapy and IMRT with subcutaneous amifostine (Ethyol, WR-2721)
Study: 1901076
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue‐type plasminogen activator (rtPA) 100 mg
Study: 31348731
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of MenAC-TT vaccine
Study: 31348731
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of MenAC-TT vaccine
Study: 31348731
Drug: Both 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 1 and 2 doses of MenAC-TT vaccine
Study: 28667881
Drug: Eye Movement
Normalized name: JOINT MOVEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye Movement Desensitization and Reprocessing (EMDR) therapy
Study: 19190912
Drug: Urokinase instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase instillation (thrice daily)
Study: 17552960
Drug: Sildenafil (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (25, 50 or 100 mg)
Study: 17552960
Drug: Tadalafil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (10 or 20 mg)
Study: 16109114
Drug: Buspirone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (10 mg/day) for 6 weeks
Study: 9536583
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler and Accuhaler
Study: 7971707
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution of felodipine
Study: 22863216
Drug: IL18 rs360719
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL18 rs360719 CC genotype
Study: 22863216
Drug: IL18 rs360719
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL18 rs360719 CC combined with IL12A rs568408 GG
Study: 22863216
Drug: IL18 rs360719
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL18 rs360719 CC combined with IL12A rs568408 GA
Study: 22863216
Drug: IL18 rs360719
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL18 rs360719 CC combined with IL12A rs568408 GG/AA
Study: 22863216
Drug: IL12B rs3212227
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL12B rs3212227 AA combined with IL18 rs360719 CC
Study: 22863216
Drug: rs3212227 CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: rs3212227 CC and rs360719 TC genotypes
Study: 14681845
Drug: Stevioside (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stevioside (1 g)
Study: 14681845
Drug: Maize starch
Normalized name: Maize starch
DrugBank: Starch, corn (DB11599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maize starch (1 g)
Study: 11642632
Drug: DTaP‐HB with
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP‐HB with licensed IPV (IPOL) administered separately
Study: 11642632
Drug: Separate doses
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate doses of OPV, DTaP, and HB
Study: 8311205
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine infusion at 7 ml.h‐1 of a 0.25% solution
Study: 8311205
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine infusion at 25 ml.h‐1 of a 0.07% solution
Study: 343727
Drug: naproxen (500-750
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen (500-750 mg daily)
Study: 343727
Drug: phenylbutazone (400-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: phenylbutazone (400-600 mg daily)
Study: 20737495
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg/2 mL IV
Study: 20737495
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% 2 mL IV
Study: 11333173
Drug: Flecainide (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (low-dose oral)
Study: 30549145
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (wives on chemotherapy)
Study: 21205628
Drug: i.v. lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. lidocaine (Group L, n=35)
Study: 21205628
Drug: i.v. lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. lidocaine (Group L)
Study: 16533388
Drug: Heart failure
Normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart failure self-management program for patients with low literacy; education on self-care, daily weight measurement, diuretic dose self-adjustment, symptom recognition, picture-based materials, digital scale, scheduled follow-up.
Study: 9920082
Drug: Low isoflavone
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low isoflavone diet (64 +/‐ 9.2 mg/day)
Study: 9920082
Drug: High isoflavone
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High isoflavone diet (128 +/‐ 16 mg/day)
Study: 9920082
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (10 +/‐ 1.1 mg/day)
Study: 7593708
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of triazolam (0.25 mg)
Study: 7593708
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of triazolam (0.25 mg)
Study: 7593708
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of triazolam (0.25 mg)
Study: 2256974
Drug: Oxpentifylline 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxpentifylline 400 mg three times a day for six months
Study: 24056528
Drug: Emixustat (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emixustat (5, 10, 20, 30, or 40 mg)
Study: 20459744
Drug: Standard-dose cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose cyclophosphamide, doxorubicin and fluorouracil (CAF)